公开(公告)号：EP0853618B1

公开(公告)日：2011-08-17

申请号：EP96919298.8

申请日：1996-06-07

申请人： Aventis Pharmaceuticals Inc.

发明人： EWING, William, R. ,  BECKER, Michael, R. ,  PAULS, Henry, W. ,  CHENEY, Daniel, L. ,  MASON, Jonathan, Stephen ,  SPADA, Alfred, P. ,  CHOI-SLEDESKI, Yong, Mi

IPC分类号： C07D207/26 ,  A61K31/40 ,  C07D407/12 ,  C07D401/12 ,  A61K31/47 ,  C07D409/14 ,  A61K31/44 ,  C07D207/14 ,  C07D207/40 ,  C07D211/76 ,  A61K31/445 ,  C07D223/12 ,  A61K31/55 ,  C07D409/12 ,  C07D403/12 ,  A61K31/505 ,  C07D205/085 ,  A61K31/395 ,  A61K31/415 ,  C07D401/06 ,  C07D409/06 ,  C07D407/06

CPC分类号： C07D207/273 ,  C07D205/085 ,  C07D207/14 ,  C07D207/416 ,  C07D211/76 ,  C07D223/12 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/06 ,  C07D405/12 ,  C07D409/06 ,  C07D409/12 ,  C07D409/14

摘要： The compounds of formula (I) exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula (I), compositions containing compounds of formula (I), and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.